Hemostasis disorders, thrombosis, antiphospholipid antibodies in patients with COVID-19
- Authors: Reshetnyak T.M.1,2, Chel'dieva F.A.1,2, Lila A.M.1,2, Nasonov E.L.1,3
-
Affiliations:
- Nasonova Research Institute of Rheumatology
- Russian Medical Academy of Continuous Professional Education
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 23, No 1 (2021)
- Pages: 35-42
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95401
- DOI: https://doi.org/10.26442/20751753.2021.1.200607
- ID: 95401
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana M. Reshetnyak
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Email: t_reshetnyak@yahoo.com
д-р мед. наук, проф., зав. лаб. сосудистой ревматологии Moscow, Russia
Fariza A. Chel'dieva
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Educationмл. науч. сотр. лаб. сосудистой ревматологии Moscow, Russia
Aleksandr M. Lila
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Educationд-р мед. наук, проф., дир. Moscow, Russia
Evgenii L. Nasonov
Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)акад. РАН, д-р мед. наук, проф., гл. науч. сотр. Moscow, Russia
References
- Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) in the U.S, 2020. Available at: https://www.cdc.goV/coronavirus/2019-ncov/cases-in-us.html# investigation
- National Institute of Allergy and Infectious Diseases. Coronaviruses, 2020. Available at: https://www.niaid.nih.gov/di-seases-conditions/coronaviruses
- Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-managementpatientshtml
- Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020; 58 (2): 123-32
- Насонов Е.Л., Бекетова Т.В., Решетняк Т.М., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020; 58: (4) 353-67
- Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020. DOI: 10.1016/ S2352-3026(20)30145-149
- Макацария А.Д., Григорьева К.Н., Мингалимов М.А., и др. Коронавирусная инфекция (COVID-19) и синдром диссеминированного внутрисосудистого свертывания. Акушерство, Г инекология и Репродукция. 2020; 14 (2)
- Loof TG, Schmidt O, Herwald H, et al. Coagulation systems of invertebrates and vertebrates and their roles in innate immunity: the same side of two coins? J Innate Immun 2011; 3 (1): 34-40. doi: 10.1159/000321641. PMID: 21051879
- Esmon CT, Esmon NL. The link between vascular features and thrombosis. Ann Rev Physiol 2011; 73: 503-14. doi: 10.1146/annurev-physiol-012110-142300; PMID: 20887194
- Струкова С.М. Основы физиологии гемостаза. Учеб. пособие. 2-е изд., перераб. и доп. М.: МГУ, 2013; c. 148-84
- Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30. doi: 10.1111/j.1365-2141.2005.05753.x
- Чельдиева Ф.А., Решетняк Т.М. Ревматоидный артрит, некоторые компоненты гемостаза и воспаление. Соврем. ревматология. 2019; 13 (3): 87-94
- Henry BM, Santos de Oliveira MH, Stefanie Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020. doi: 10.1515/cclm-2020-0369
- Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382 (18): 1708-20. doi: 10.1056/NEJMoa2002032; PMID: 32109013; PMCID: PMC7092819
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (4): 844-7. doi: 10.1111/jth.14768; PMID: 32073213; PMCID: PMC7166509
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5; PMID: 31986264; PMCID: PMC7159299
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-62. doi: 10.1016/S0140-6736(20)30566-3; PMID: 32171076; PMCID: PMC7270627
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J He-matol 2020. doi: 10.1002/ajh.25829
- Thachil J, Wada H, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020. doi: 10.1111/jth.14810
- Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-8. doi: 10.1016/j.cca.2020.03.022; PMID: 32178975; PMCID: PMC7102663
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-4. doi: 10.1016/S0140-6736(20)30628-0; PMID: 32192578; PMCID: PMC7270045
- Thachil J. Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective. Semin Thromb Hemost 2015; 41 (6): 572-81. doi: 10.1055/s-0035-1556589
- Borensztajn KS, von der Thusen JH, Spek CA. The role of coagulation in chronic inflammatory disorders: A jack of all trades. Curr Pharm Des 2011; 17 (1): 9-16. doi: 10.2174/138161211795049813
- Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020. doi: 10.1016/j.thromres.2020.04.013
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2): 295-306. doi: 10.1111/j.1538-7836.2006.01753; PMID: 16420554
- Насонов Е.Л. Антифосфолипидный синдром. Монография. М.: Литтера, 2004; с. 36
- Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научнопрактическая ревматология. 2014; 52 (1): 56-71
- Буланов Н.М., Козловская Н.Л., Моисеев С.В., и др. Сочетание АНЦА-ассоциированного васкулита и атипичного гемолитико-уремического синдрома у пациентки с мутацией гена диацилглицеролкиназы-эпсилон (Клинический разбор). Нефрология и диализ. 2018. 20 (2): 212-24
- Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol 1992; 19: 1474-8. PMID: 14 33020.
- Harzallah I, Debliquis A, Drenou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020; 18: 2064-5. DOI: 10.1111/ jth.14867
- Pineton de Chambrun M, Frere C, Miyara M, et al. High Frequency of Antiphospholipid Antibodies in Critically-ill COVID-19 Patients: a Link with Hypercoagulability? J Int Med 2020; 12. doi: 10.1111/joim.13126
- Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020; 382: e38. doi: 10.1056/NEJMc2007575
- Zuo Y, Estes SK, Gandhi AA, et al. Prothrombotic antiphospholipid antibodies in COVID-19. medRxiv 2020; 17. DOI: 10.1101/ 2020.06.15.20131607
- Xiao M, Zhang Y, Zhang S, et al. Brief Report: Antiphospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID-19). Arthritis Rheumatol 2020. doi: 10.1002/art.41425
- Leroy V, Arvieux J, Jacob MC, et al. Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C. Br J Haematol 1998; 101 (3): 468-74. doi: 10.1046/j.1365-2141.1998.00722; PMID: 9633888
- Gharavi EE, Chaimovich H, Cucurull E, et al. Induction of antiphospholipid antibodies by immunization with syntetic viral and bacterial peptidies. Lupus 1999; 8: 449-55. doi: 10.1177/096120339900800607
- Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (4): 256-63. doi: 10.1053/sarh.2002.28303
- Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Ne-urosurg Psychiatry 2020; 91 (8): 889-91. doi: 10.1136/jnnp-2020-323586
- Devreese KMJ, Ortel TL, Pengo V, et al. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (4): 809-13. doi: 10.1111/jth.13976
- Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost 2016; 14 (8): 1530-48. doi: 10.1111/jth.13379
- Chayoua W, Kelchtermans H, Gris JC, et al. The (non-)sense of detecting anti-cardiolipin and anti-beta2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 2020; 18 (1): 169-79. doi: 10.1111/jth.14633
- Schouwers SM, Delanghe JR, Devreese KM. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res 2010; 125 (1): 102-4. doi: 10.1016/j.thromres.2009.09.001; PMID: 19782388.
- Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation? J Thromb Haemost 2020; 18 (9): 2191-201. doi: 10.1111/jth.14994
- Devreese KM. Antiphospholipid antibody testing and standardization. International Journal of Laboratory Hematology 2014; 36 (3): 352-63. doi: 10.1111/ijlh.12234
- Schouwers SM, Delanghe JR, Devreese KM. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res 2010; 125 (1): 102-4. doi: 10.1016/j.thromres.2009.09.001
- De Kesel PM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin and danaparoid on lupus anticoagulant testing. Can activated carbon eliminate false positive results? Res Practice Thromb Haemost 2019. doi: 10.1002/rth1002.12264
- Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2020. doi: 10.1111/jth.14846
- Galeano-Valle F, Oblitas CM, Ferreiro-Mazon MM, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 2020; 192: 113-5. DOI: 10.1016/ j.thromres.2020.05.017
- Borghi MO, Beltagy A, Garrafa E, et al. Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Front Immunol 2020; 15; 11: 584241. doi: 10.3389/fimmu.2020.584241
- Tincani A, Morozzi G, Afeltra A, et al. Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol 2007; 25 (2): 268-74. PMID: 17543152.
- Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. New Engl J Med 2020. doi: 10.1056/NEJMc2013656
- Sanchez-Zamora P, de la Flor-Robledo M. Acute lung injury as a consequence of fresh frozen plasma administration in a patient with factor XII deficiency. Rev Esp Anestesiol Reanim 2014; 61 (8): 446-50. doi: 10.1016/j.redar.2013.09.012; PMID: 24252352.
- Cornudella R, Puente F, Hortells JL, Gutierrez M. Moderate deficiency of Factor XII associated with postoperative deep venous thrombosis. Sangre (Barc) 1989; 34 (2): 144-6. PMID: 2756451.
- Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: A novel therapeutic target. J Allergy Clin Immunol 2020; 146: 215-17. doi: 10.1016/j.jaci.2020.05.006
- Garcia-Carrasco M, Galarza-Maldonado C, Mendoza-Pinto C, et al. Infections and the Antiphospholipid Syndrome. Clin Rev Allergy Immunol 2009; 36: 104-8. doi: 10.1007/s12016-008-8103-0
- Wyman B, Perl A. Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases. Curr Opin Rheumatol 2020; 32: 184-91. doi: 10.1097/BOR.0000000000000687
- Available from: https://www.outcomesumassmed.org/IMPROVE/risk_score/index.html
- Tapson VF, Decousus H, Pini M, et al. IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007; 132 (3): 936-45. doi: 10.1378/chest.06-2993; PMID: 17573514.
- Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140 (3): 706-14. doi: 10.1378/chest.10-1944; PMID: 21436241.
- Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136 (4): 489-500. doi: 10.1182/blood.2020006520; PMID: 32492712; PMCID: PMC7378457.
- Conti CB, Henchi S, Coppeta GP, et al. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern? Eur J Intern Med 2020; 77: 147-9. doi: 10.1016/j.ejim.2020.05.002
- Jang JY, Lim YS, Woo JH, et al. Spontaneous rupture of intercostal artery after severe cough. Am J Emerg Med 2015; 33 (1): 131. doi: 10.1016/j.ajem.2014.06.033
- Lee CH, Lan CC, Wang CC, et al. Spontaneous rupture of gastroduodenal artery pseudoaneurysm following vigorous cough. Am J Gastroenterol 2009; 104 (2): 529-30. doi: 10.1038/ajg.2008.52
- Dorgalaleh A. Bleeding and Bleeding Risk in COVID-19. Semin Thromb Hemost 2020; 46 (7): 815-8. doi: 10.1055/s-0040-1713434
- Joob B, Wiwanitkit V. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients. Clin Appl Thromb Hemost 2020; 26: 1076029620918308. doi: 10.1177/1076029620918308
- Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology 2020; 296 (2): E119-20. doi: 10.1148/radiol.2020201187
- Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andres E. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Engl J Med 2020; 382 (18): e43. doi: 10.1056/NEJMc2010472; PMID: 32294340; PMCID: PMC7179995.
- Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020. doi: 10.1016/j.jacc.2020.04.031
- Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment. J Thromb Haemost 2020. doi: 10.1111/jth.14860
- Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost 2020. doi: 10.1111/jth.14871
- Liu X, Zhang X, Xiao Y, et al. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. medRxiv 2020. doi: 10.1101/2020.04.23.20076851
- Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus 2020. doi: 10.2450/2020.0083-20
- Preventing Hospital-Associated Venous Thromboembolism. A Guide for Effective Quality Improvement. Available at: https://www.ahrq.gov/sites/default/files/publications/files/vteguide.pdf